News & Press > Novexatin® Phase I Concludes
25th August 2009
Phase I Clinical Study for Novexatin® Concludes
NovaBiotics announces today that its Phase I clinical study to determine safety and tolerability of Novexatin® in patients with mild to moderate onychomycosis has successfully concluded.
Registered in Scotland No. SC272344. Registered Address: NovaBiotics Ltd, Cruickshank Building, Craibstone, Aberdeen, AB21 9TR, UK
© NovaBiotics Ltd 2009.
All Rights Reserved
Last updated
22 October, 2009
